Bristol Myers Squibb (CELG-RI) Amortizatization of Intangibles (2009 - 2012)

Bristol Myers Squibb (CELG-RI) reported Amortizatization of Intangibles of $102.0 million for Q2 2012, up 7.37% year-over-year from $95.0 million in Q3 2011, and up 0.99% quarter-over-quarter from $101.0 million in Q1 2012.

Bristol Myers Squibb (CELG-RI) Amortizatization of Intangibles (2009 - 2012) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has 4 years of Amortizatization of Intangibles data on file, last reported at $102.0 million in Q2 2012.

  • Amortizatization of Intangibles for Q2 2012 came in at $102.0 million, up 7.37% year-over-year; the trailing twelve-month figure through Jun 2012 was $388.0 million (up 26.38% YoY), and the FY2011 annual result was $353.0 million, up 30.26% from the prior year.
  • Amortizatization of Intangibles climbed to $102.0 million in Q2 2012 per CELG-RI's latest filing, from $101.0 million in the prior quarter.
  • Over five years, Amortizatization of Intangibles peaked at $102.0 million in Q2 2012 and troughed at $59.0 million in Q3 2009.
  • A 4-year average of $80.3 million and a median of $75.5 million in 2009 frame the typical range for Amortizatization of Intangibles.
  • The sharpest annual moves came in 2010 and 2011: Amortizatization of Intangibles dropped 6.41% in 2010, then jumped 41.79% in 2011.
  • A 4-year view of Amortizatization of Intangibles shows it stood at $78.0 million in 2009, then retreated by 6.41% to $73.0 million in 2010, then grew by 26.03% to $92.0 million in 2011, then rose by 10.87% to $102.0 million in 2012.
  • Business Quant data shows CELG-RI's Amortizatization of Intangibles at $102.0 million in Q2 2012, $101.0 million in Q1 2012, and $92.0 million in Q4 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 1.70 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 931.00 Mn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 596.00 Mn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -
10 Bristol Myers Squibb - - 8.07 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2012 102.00 Mn
Jun 30, 2012 102.00 Mn
Mar 31, 2012 101.00 Mn
Mar 31, 2012 101.00 Mn
Dec 31, 2011 92.00 Mn
Dec 31, 2011 92.00 Mn
Sep 30, 2011 93.00 Mn
Sep 30, 2011 93.00 Mn
Jun 30, 2011 95.00 Mn
Jun 30, 2011 95.00 Mn
Mar 31, 2011 73.00 Mn
Mar 31, 2011 73.00 Mn
Dec 31, 2010 73.00 Mn
Dec 31, 2010 73.00 Mn
Sep 30, 2010 66.00 Mn
Sep 30, 2010 66.00 Mn
Jun 30, 2010 67.00 Mn
Jun 30, 2010 67.00 Mn
Mar 31, 2010 65.00 Mn
Mar 31, 2010 65.00 Mn